Prot# SGN35-005: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 (brentuximab vedotin) and Best Supportive Care (BSC) versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma (HL) Following Auto

Project: Research project

Project Details

StatusFinished
Effective start/end date12/15/1212/15/18

Funding

  • Seattle Genetics, Inc. (SGN35-005)